Adrian C Newland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Adrian C Newland has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
A. Copplestone
Derriford (Plymouth)
1 shared publicationAz Rohatiner
St Bartholomew's Hospital
1 shared publicationC. Brown
1 shared publication- Cristina V. Navarrete
NHS-Cord Blood Bank, NHSBT, London, UK
1 shared publication D. McCloskey
1 shared publicationD. Provan
1 shared publication
Latest Publications
- 1 January 2002
- Published by Elsevier in The Lancet
- Vol. 359 (9300) , 4-5
Treatment of adults with autoimmune thrombocytopenic purpura
- 1 January 2002
- Published by Elsevier in The Lancet
- Vol. 359 (9300) , 4-5
Treatment of adults with autoimmune thrombocytopenic purpura
- 1 January 2002
- Published by Taylor & Francis in Hematology
- Vol. 7 (2) , 119-121
Major Histocompatibility Complex Susceptibility Genes and Immune Thrombocytopenic Purpura in Caucasian Adults
Immune thrombocytopenic purpura (ITP) is a heterogeneous disorder with wide variability in response rates to treatments including corticosteroids, splenectomy and intravenous immune globulins. The nature of the underlying predisposing causes for this autoimmune disorder are not known. We have HLA typed 71 adult Caucasian patients with chronic primary ITP, and compared the data with 750 control samples. In this association study, we were not able to identify a significant immunogenetic susceptibility factor for ITP with HLA class I and class II alleles. However, it appeared that there might be an association between HLA-A2 and ITP, particularly in female patients, who are the predominantly affected group; and HLA-A2 was also present at increased frequency in patients with chronic ITP progressing to splenectomy. These findings are reviewed in the context of other similar reported HLA studies in ITP. Further studies based on larger groups of patients will be necessary to identify genetic susceptibility factors for this disease.
- 1 January 2002
- Published by Taylor & Francis in Hematology
- Vol. 7 (2) , 119-121
Major Histocompatibility Complex Susceptibility Genes and Immune Thrombocytopenic Purpura in Caucasian Adults
Immune thrombocytopenic purpura (ITP) is a heterogeneous disorder with wide variability in response rates to treatments including corticosteroids, splenectomy and intravenous immune globulins. The nature of the underlying predisposing causes for this autoimmune disorder are not known. We have HLA typed 71 adult Caucasian patients with chronic primary ITP, and compared the data with 750 control samples. In this association study, we were not able to identify a significant immunogenetic susceptibility factor for ITP with HLA class I and class II alleles. However, it appeared that there might be an association between HLA-A2 and ITP, particularly in female patients, who are the predominantly affected group; and HLA-A2 was also present at increased frequency in patients with chronic ITP progressing to splenectomy. These findings are reviewed in the context of other similar reported HLA studies in ITP. Further studies based on larger groups of patients will be necessary to identify genetic susceptibility factors for this disease.
- Open Access
- 1 September 2001
- Published by Elsevier in Clinical Medicine
- Vol. 1 (5) , 378-382
Stem cells: progress in research and edging towards the clinical setting
Mouse embryonic stem cells have been shown to differentiate into a variety of tissues in vitro and in transplantation experiments can produce many different cell types. Multipotent stem cells in adult humans have also shown a high degree of plasticity: haemopoietic stem cells, for example, have been shown to contribute to several other tissues, such as liver. From these simple observations there has been considerable extrapolation into the use of such putative totipotent stem cells in the clinical setting, with the development of 'designer' tissue engineering, whose aim is to create large tissues or even whole organs for clinical use. In practical terms, however, there are many limitations and difficulties and clinical use has been restricted to a very few settings, eg the use of fetal cells in Parkinson's disease. Nonetheless, there is enormous potential in this area, and also in the application of embryonic or adult stem cells as carriers for gene therapy; but the limitations of such treatment, in particular the stability of manipulated cells, and the problems of ageing and Ooncogenicity, not to mention a host of ethical and regulatory issues, all need to be considered.
- 1 September 2001
- Published by Elsevier in Clinical Medicine
- Vol. 1 (5) , 378-382
Open AccessStem cells: progress in research and edging towards the clinical setting
Mouse embryonic stem cells have been shown to differentiate into a variety of tissues in vitro and in transplantation experiments can produce many different cell types. Multipotent stem cells in adult humans have also shown a high degree of plasticity: haemopoietic stem cells, for example, have been shown to contribute to several other tissues, such as liver. From these simple observations there has been considerable extrapolation into the use of such putative totipotent stem cells in the clinical setting, with the development of 'designer' tissue engineering, whose aim is to create large tissues or even whole organs for clinical use. In practical terms, however, there are many limitations and difficulties and clinical use has been restricted to a very few settings, eg the use of fetal cells in Parkinson's disease. Nonetheless, there is enormous potential in this area, and also in the application of embryonic or adult stem cells as carriers for gene therapy; but the limitations of such treatment, in particular the stability of manipulated cells, and the problems of ageing and Ooncogenicity, not to mention a host of ethical and regulatory issues, all need to be considered.
- 1 February 2001
- Published by Wiley in Transfusion Medicine
- Vol. 11 (1) , 37-44
Vigam‐S, a solvent/detergent‐treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura
. The efficacy of Vigam‐S, a highly purified intravenous immunoglobulin, was investigated by an open, noncomparative study in 20 adults with chronic idiopathic thrombocytopenic purpura (ITP). Fifteen patients responded to the initial 3‐day infusion of 0·4 g kg −1 day−1 by exhibiting an incremental increase in platelet count of ≥ 30 × 109 L−1, in eight of whom platelet count normalized (> 150 × 109 L−1). The peak platelet count for responders on day 4 was 163 × 109 L−1 (baseline = 18 × 109 L−1). No benefit was derived from an extra 2 days infusion in nonresponders. Further treatment (either a single 0·8 g kg−1 dose or another 3‐day infusion) given to responders when platelet counts fell below 30 × 109 L−1 was effective on eight of 14 occasions. Increases in total serum IgG concentration (to a mean peak of 25·3 g L−1) were not correlated with platelet response. There was no evidence of seroconversion to virus markers, or of alteration in renal function, following Vigam‐S infusion. Most adverse events were mild and transient; however, three patients had severe headache and vomiting (possible aseptic meningitis syndrome) and one had marked superficial thrombophlebitis. Therefore Vigam‐S provides effective and well tolerated therapy in the management of adults with ITP although individual patient response remains difficult to predict.
- 1 February 2001
- Published by Wiley in Transfusion Medicine
- Vol. 11 (1) , 37-44
Vigam‐S, a solvent/detergent‐treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura
. The efficacy of Vigam‐S, a highly purified intravenous immunoglobulin, was investigated by an open, noncomparative study in 20 adults with chronic idiopathic thrombocytopenic purpura (ITP). Fifteen patients responded to the initial 3‐day infusion of 0·4 g kg −1 day−1 by exhibiting an incremental increase in platelet count of ≥ 30 × 109 L−1, in eight of whom platelet count normalized (> 150 × 109 L−1). The peak platelet count for responders on day 4 was 163 × 109 L−1 (baseline = 18 × 109 L−1). No benefit was derived from an extra 2 days infusion in nonresponders. Further treatment (either a single 0·8 g kg−1 dose or another 3‐day infusion) given to responders when platelet counts fell below 30 × 109 L−1 was effective on eight of 14 occasions. Increases in total serum IgG concentration (to a mean peak of 25·3 g L−1) were not correlated with platelet response. There was no evidence of seroconversion to virus markers, or of alteration in renal function, following Vigam‐S infusion. Most adverse events were mild and transient; however, three patients had severe headache and vomiting (possible aseptic meningitis syndrome) and one had marked superficial thrombophlebitis. Therefore Vigam‐S provides effective and well tolerated therapy in the management of adults with ITP although individual patient response remains difficult to predict.
- 1 August 2000
- Published by Springer Nature in Medical Oncology
- Vol. 17 (4) , 333-336
Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide
A 36-year-old man underwent matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia. He developed severe hepatic veno-occlusive disease as an early post-transplant complication. Tissue plasminogen activator was initially felt to be contraindicated since the patient had concomitant pericarditis. Defibrotide was therefore commenced as treatment for veno-occlusive disease. The pericarditis improved but the veno-occlusive disease continued to worsen (peak bilirubin 353 μmol/I). Tissue plasminogen activator followed by a heparin infusion was therefore administered. However, he proceeded to develop haemorrhagic cardiac tamponade that required drainage. Thrombolysis was therefore discontinued and treatment with defibrotide resumed after an interval of 48 h. The veno-occlusive disease gradually resolved and defibrotide was discontinued once the bilirubin had plateaued. He was discharged home on day +52 post-transplant.
- 1 August 2000
- Published by Springer Nature in Medical Oncology
- Vol. 17 (4) , 333-336
Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide
A 36-year-old man underwent matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia. He developed severe hepatic veno-occlusive disease as an early post-transplant complication. Tissue plasminogen activator was initially felt to be contraindicated since the patient had concomitant pericarditis. Defibrotide was therefore commenced as treatment for veno-occlusive disease. The pericarditis improved but the veno-occlusive disease continued to worsen (peak bilirubin 353 μmol/I). Tissue plasminogen activator followed by a heparin infusion was therefore administered. However, he proceeded to develop haemorrhagic cardiac tamponade that required drainage. Thrombolysis was therefore discontinued and treatment with defibrotide resumed after an interval of 48 h. The veno-occlusive disease gradually resolved and defibrotide was discontinued once the bilirubin had plateaued. He was discharged home on day +52 post-transplant.